Krystal Biotech, Inc. (KRYS)
300.88
+0.63
(+0.21%)
USD |
NASDAQ |
Nov 06, 16:00
299.88
-1.00
(-0.33%)
After-Hours: 20:00
Krystal Biotech Research and Development Expense (Quarterly) : 13.42M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 13.42M |
| June 30, 2026 | 13.16M |
| March 31, 2026 | 13.81M |
| December 31, 2025 | 13.23M |
| September 30, 2025 | 13.18M |
| June 30, 2025 | 14.41M |
| March 31, 2025 | 14.26M |
| December 31, 2024 | 13.52M |
| September 30, 2024 | 13.51M |
| June 30, 2024 | 15.58M |
| March 31, 2024 | 10.96M |
| December 31, 2023 | 11.37M |
| September 30, 2023 | 10.63M |
| June 30, 2023 | 12.14M |
| March 31, 2023 | 12.29M |
| December 31, 2022 | 9.741M |
| September 30, 2022 | 10.85M |
| June 30, 2022 | 10.40M |
| March 31, 2022 | 8.852M |
| December 31, 2021 | 8.609M |
| September 30, 2021 | 5.606M |
| June 30, 2021 | 6.119M |
| Date | Value |
|---|---|
| March 31, 2021 | 5.763M |
| December 31, 2020 | 5.672M |
| September 30, 2020 | 5.10M |
| June 30, 2020 | 3.639M |
| March 31, 2020 | 3.525M |
| December 31, 2019 | 4.349M |
| September 30, 2019 | 3.885M |
| June 30, 2019 | 4.216M |
| March 31, 2019 | 3.167M |
| December 31, 2018 | 2.802M |
| September 30, 2018 | 1.914M |
| June 30, 2018 | 1.525M |
| March 31, 2018 | 1.52M |
| December 31, 2017 | 1.088M |
| September 30, 2017 | 1.355M |
| June 30, 2017 | 0.446M |
| March 31, 2017 | 0.319M |
| December 31, 2016 | 0.402M |
| September 30, 2016 | 0.241M |
| June 30, 2016 | 0.098M |
| March 31, 2016 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 408.54M |
| Ionis Pharmaceuticals, Inc. | 216.41M |
| Ultragenyx Pharmaceutical, Inc. | 145.00M |
| BridgeBio Pharma, Inc. | 143.51M |
| Cytokinetics, Inc. | 95.64M |